NDAQ
57
2
PYPL
32
3
NWSA
42
-18
TXT
70
-2
PGR
40
3
EXPE
54
-2
PCAR
56
11
MCK
64
2
CI
45
2
EQT
65
-3
MUR
49
2
V
40
4
MKC
38
2
COST
53
2
IFF
48
-2
HP
36
2
HIG
54
-8
DOW
62
2
MDLZ
34
4
SWKS
37
6
NDAQ
57
2
PYPL
32
3
NWSA
42
-18
TXT
70
-2
PGR
40
3
EXPE
54
-2
PCAR
56
11
MCK
64
2
CI
45
2
EQT
65
-3
MUR
49
2
V
40
4
MKC
38
2
COST
53
2
IFF
48
-2
HP
36
2
HIG
54
-8
DOW
62
2
MDLZ
34
4
SWKS
37
6
Financhill
Back

Mineralys Therapeutics, Inc. 10K Form

Sell
38

MLYS
Mineralys Therapeutics, Inc.

Last Price:
$27.01
Seasonality Move:
1.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MLYS News And Ratings

See the #1 stock for the next 7 days that we like better than MLYS

MLYS Financial Statistics

Sales & Book Value

Annual Sales: $0
Cash Flow: $-37.9M
Price / Cash Flow: 0
Annual Sales: $7.93
Price / Book: 3.51

Profitability

EPS (TTM): -2.37860
Net Income (TTM): $-154.7M
Gross Margin: $-59K
Return on Equity: -37.37%
Return on Assets: -35.83%

Mineralys Therapeutics, Inc. Earnings Forecast

Key Mineralys Therapeutics, Inc. Financial Ratios

  • Per Share Earnings over the last 6 years have been positive in 1 years.

Mineralys Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MLYS
Website: mineralystx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 43.76
Quick Ratio: 43.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MLYS Technical Analysis vs Fundamental Analysis

Sell
38
Mineralys Therapeutics, Inc. (MLYS) is a Sell

Is Mineralys Therapeutics, Inc. a Buy or a Sell?